Repurposing Drugs in Small Animal Oncology

Overview

Journal Animals (Basel)

Date 2023 Jan 8

PMID 36611747

Authors

Antonio Giuliano

Rodrigo S Horta

Rafael A M Vieira

Kelly R Hume

Jane Dobson

Affiliations

Soon will be listed here.

Abstract

Repurposing drugs in oncology consists of using off-label drugs that are licensed for various non-oncological medical conditions to treat cancer. Repurposing drugs has the advantage of using drugs that are already commercialized, with known mechanisms of action, proven safety profiles, and known toxicology, pharmacokinetics and pharmacodynamics, and posology. These drugs are usually cheaper than new anti-cancer drugs and thus more affordable, even in low-income countries. The interest in repurposed anti-cancer drugs has led to numerous in vivo and in vitro studies, with some promising results. Some randomized clinical trials have also been performed in humans, with certain drugs showing some degree of clinical efficacy, but the true clinical benefit for most of these drugs remains unknown. Repurposing drugs in veterinary oncology is a very new concept and only a few studies have been published so far. In this review, we summarize both the benefits and challenges of using repurposed anti-cancer drugs; we report and discuss the most relevant studies that have been previously published in small animal oncology, and we suggest potential drugs that could be clinically investigated for anti-cancer treatment in dogs and cats.

Citing Articles

Some Aspects and Convergence of Human and Veterinary Drug Repositioning.

Mag P, Nemes-Terenyi M, Jerzsele A, Matyus P Molecules. 2024; 29(18).

PMID: 39339469 PMC: 11433938. DOI: 10.3390/molecules29184475.

Multimodal Blockade of the Renin-Angiotensin System in the Treatment of Cancer in Dogs Has Mild Adverse Effects in Some Dogs.

Dittmer K, Wetzel S, Odom T, Munday J, Flatt E, Wilson I Vet Sci. 2024; 11(6).

PMID: 38922022 PMC: 11209120. DOI: 10.3390/vetsci11060275.

Machine learning determines stemness associated with simple and basal-like canine mammary carcinomas.

Xavier P, Marcao M, Simoes R, Job M, de Francisco Strefezzi R, Fukumasu H Heliyon. 2024; 10(5):e26714.

PMID: 38439848 PMC: 10909659. DOI: 10.1016/j.heliyon.2024.e26714.

Molecular Profile of Canine Hemangiosarcoma and Potential Novel Therapeutic Targets.

Bronhara Pimentel P, Giuliano A, Beczkowski P, Horta R Vet Sci. 2023; 10(6).

PMID: 37368773 PMC: 10302982. DOI: 10.3390/vetsci10060387.

References

Gupte A, Baker E, Wan S, Stewart E, Loh A, Shelat A . Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clin Cancer Res. 2015; 21(14):3216-29. PMC: 4506243. DOI: 10.1158/1078-0432.CCR-14-3026. View

Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Branes J . Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med. 2009; 14(5):1180-93. PMC: 3822754. DOI: 10.1111/j.1582-4934.2009.00771.x. View

Assayag F, Brousse N, Couturier J, Macintyre E, Mathiot C, Dewulf S . Experimental treatment of human diffuse large B-cell lymphoma xenografts by doxycycline alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab. Am J Hematol. 2009; 84(6):387-8. DOI: 10.1002/ajh.21415. View

Kalinichenko V, Mokyr M, Graf Jr L, Cohen R, CHAMBERS D . Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression. J Immunol. 1999; 163(5):2492-9. View

Matusewicz L, Meissner J, Toporkiewicz M, Sikorski A . The effect of statins on cancer cells--review. Tumour Biol. 2015; 36(7):4889-904. DOI: 10.1007/s13277-015-3551-7. View

Misirkic M, Janjetovic K, Vucicevic L, Tovilovic G, Ristic B, Vilimanovich U . Inhibition of AMPK-dependent autophagy enhances in vitro antiglioma effect of simvastatin. Pharmacol Res. 2011; 65(1):111-9. DOI: 10.1016/j.phrs.2011.08.003. View

Mosallanejad B, Avizeh R, Razi Jalali M, Pourmahdi M . Comparative evaluation between chitosan and atorvastatin on serum lipid profile changes in hyperlipidemic cats. Iran J Vet Res. 2016; 17(1):36-40. PMC: 4898018. View

Wagner B, Johnson J, Garcia-Tapia D, Honsberger N, King V, Strietzel C . Comparison of effectiveness of cefovecin, doxycycline, and amoxicillin for the treatment of experimentally induced early Lyme borreliosis in dogs. BMC Vet Res. 2015; 11:163. PMC: 4513938. DOI: 10.1186/s12917-015-0475-9. View

Klose K, Packeiser E, Muller P, Granados-Soler J, Schille J, Goericke-Pesch S . Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line. PLoS One. 2021; 16(9):e0257403. PMC: 8476037. DOI: 10.1371/journal.pone.0257403. View

10.

Kaufmann J, Vischer U . Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost. 2003; 1(4):682-9. DOI: 10.1046/j.1538-7836.2003.00190.x. View

11.

Ripoll G, Farina H, Yoshiji H, Gomez D, Alonso D . Desmopressin reduces melanoma lung metastasis in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1. In Vivo. 2007; 20(6B):881-5. View

12.

Saeki K, Watanabe M, Tsuboi M, Sugano S, Yoshitake R, Tanaka Y . Anti-tumour effect of metformin in canine mammary gland tumour cells. Vet J. 2015; 205(2):297-304. DOI: 10.1016/j.tvjl.2015.04.026. View

13.

Pulvino M, Chen L, Oleksyn D, Li J, Compitello G, Rossi R . Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. Oncotarget. 2015; 6(17):14796-813. PMC: 4558116. DOI: 10.18632/oncotarget.4193. View

14.

Hume K, Sylvester S, Borlle L, Balkman C, McCleary-Wheeler A, Pulvino M . Metabolic Abnormalities Detected in Phase II Evaluation of Doxycycline in Dogs with Multicentric B-Cell Lymphoma. Front Vet Sci. 2018; 5:25. PMC: 5834767. DOI: 10.3389/fvets.2018.00025. View

15.

Yin M, Zhou J, Gorak E, Quddus F . Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist. 2013; 18(12):1248-55. PMC: 3868417. DOI: 10.1634/theoncologist.2013-0111. View

16.

Boige V, Malka D, Ducreux M . [Therapeutic strategies using VEGF inhibitors in colorectal cancer]. Bull Cancer. 2006; 92(Spec no):S29-36. View

17.

Saha J, Kim J, Amaya C, Witcher C, Khammanivong A, Korpela D . Propranolol Sensitizes Vascular Sarcoma Cells to Doxorubicin by Altering Lysosomal Drug Sequestration and Drug Efflux. Front Oncol. 2021; 10:614288. PMC: 7882688. DOI: 10.3389/fonc.2020.614288. View

18.

Tsou Y, Chang W, Lin C, Chang R, Tsai M, Shih L . Metformin Increases Survival in Hypopharyngeal Cancer Patients with Diabetes Mellitus: Retrospective Cohort Study and Cell-Based Analysis. Pharmaceuticals (Basel). 2021; 14(3). PMC: 7996771. DOI: 10.3390/ph14030191. View

19.

Kochuparambil S, Al-Husein B, Goc A, Soliman S, Somanath P . Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther. 2010; 336(2):496-505. DOI: 10.1124/jpet.110.174870. View

20.

Yang E, Kim S, Donovan E, Chen M, Gross A, Webster Marketon J . Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun. 2008; 23(2):267-75. PMC: 2652747. DOI: 10.1016/j.bbi.2008.10.005. View